Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name NTRK2 fusion
Gene Variant Detail

NTRK2 fusion (unknown)

Relevant Treatment Approaches Trk Receptor Inhibitor (Pan)

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04484142 Phase II Datopotamab deruxtecan Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) Completed USA | NLD | ITA | HUN | FRA | ESP | DEU 3
NCT03520686 Phase III Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Carboplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Ipilimumab + Nivolumab + Nogapendekin alfa inbakicept Carboplatin + Ipilimumab + Nab-paclitaxel + Nivolumab + Nogapendekin alfa inbakicept Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Cisplatin + Pemetrexed Disodium Nogapendekin alfa inbakicept + Pembrolizumab Atezolizumab + Carboplatin + Nab-paclitaxel Cisplatin + Pembrolizumab + Pemetrexed Disodium Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer Terminated USA 0
NCT03215511 Phase Ib/II Selitrectinib A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer Completed USA | ITA | IRL | FRA | ESP | DNK | DEU | BEL | AUS 1
NCT03994796 Phase II Adagrasib Abemaciclib GDC-0084 Entrectinib Genetic Testing in Guiding Treatment for Patients With Brain Metastases Active, not recruiting USA 0
NCT07355205 Phase Ib/II Ipilimumab + Nivolumab + Nogapendekin alfa inbakicept First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (FLINN) Recruiting USA 0
NCT07020065 Phase II Carboplatin + Cemiplimab + Gemcitabine Carboplatin + Cemiplimab + Pemetrexed Disodium Cemiplimab Carboplatin + Cemiplimab + Paclitaxel Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% Recruiting CHE 0
NCT04901806 Phase Ib/II PBI-200 Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors Terminated USA | ITA | GBR | FRA | ESP | DNK | DEU | AUS 3
NCT07217301 Phase III IBI363 Docetaxel A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer (MarsLight-11) Recruiting USA 2
NCT04581824 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Dostarlimab-gxly + Pemetrexed Disodium Carboplatin + Dostarlimab-gxly + Pemetrexed Disodium Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Terminated USA | ROU | POL | ITA | FRA | ESP | DEU | BRA | ARG 3
NCT06495125 Phase II Defactinib + Nivolumab + RO5126766 Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer Recruiting USA 0
NCT04923126 Phase Ib/II Mirdametinib SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma Recruiting USA 0
NCT04467801 Phase II Ipatasertib Docetaxel + Ipatasertib Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy (Ipat-Lung) Unknown status USA 0
NCT05469178 Phase Ib/II Bemcentinib + Carboplatin + Pembrolizumab + Pemetrexed Disodium A Clinical Study of Bemcentinib with Standard of Care Chemoimmunotherapy in Untreated Advanced/metastatic Non-small Cell Lung Cancer Patients with a Mutation in the STK11 Gene Terminated USA | POL | ITA | HUN | GRC | FRA | ESP 0
NCT05153408 Phase Ib/II BLU-701 BLU-701 + Osimertinib BLU-701 + Carboplatin + Pemetrexed Disodium (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC Terminated USA 0
NCT03827850 Phase II Erdafitinib FGFR Inhibitor in FGFR Dysregulated Cancer (FIND) Terminated DEU 0
NCT02097810 Phase I Entrectinib Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1) Completed USA 1
NCT07566052 Phase III ASP3082 Docetaxel A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation Recruiting USA 1
NCT05671510 Phase III ONC-392 Docetaxel ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003) Recruiting USA | TUR | NLD | ITA | GBR | ESP | DEU | CAN | BEL | AUS 2
NCT05785754 Phase I Doxorubicin + Tebentafusp DCSZ11 + Pembrolizumab DCSZ11 DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors Recruiting USA | AUS 2
NCT04589845 Phase II Alectinib Divarasib Entrectinib Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Active, not recruiting USA | POL | NZL | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUS 8
NCT03155620 Phase II Tazemetostat Larotrectinib Vemurafenib Ivosidenib Palbociclib Selumetinib Tipifarnib LY3023414 Selpercatinib Olaparib Ulixertinib Erdafitinib Ensartinib Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Active, not recruiting USA | CAN | AUS 1
NCT03953235 Phase Ib/II GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens Completed USA 0
NCT04655404 Phase I Larotrectinib A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma with NTRK Fusion Recruiting USA | NZL | DEU | CAN | AUS 0
NCT06307795 Phase I ANS014004 A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | CAN 1
NCT05676749 Phase I Aldesleukin + C-TIL051 + Pembrolizumab C-TIL051 in Non-Small Cell Lung Cancer Terminated USA 0
NCT05783323 Phase II Larotrectinib Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer Recruiting USA 0
NCT04270591 Phase Ib/II SCC244 Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer Recruiting USA 2
NCT07227298 Phase Ib/II SSGJ-707 SGN-B6A + SSGJ-707 Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers Recruiting USA | ITA | FRA | ESP | DEU 4
NCT04265534 Phase II Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium + Telaglenastat Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE) Terminated USA 0
NCT03213704 Phase II Larotrectinib Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT05935774 Phase II Atezolizumab + Trabedersen OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer Withdrawn USA 0
NCT04526691 Phase I Cisplatin + Datopotamab deruxtecan + Pembrolizumab Carboplatin + Datopotamab deruxtecan + Pembrolizumab Datopotamab deruxtecan + Pembrolizumab Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) Active, not recruiting USA | ITA | ESP 2
NCT05435846 Phase I Capmatinib + Trametinib Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation Terminated USA 0
NCT06094296 Phase II Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) Terminated USA | AUS 0
NCT05379595 Phase Ib/II Amivantamab-vmjw Amivantamab-vmjw + Fluorouracil + Irinotecan + Leucovorin Amivantamab-vmjw + Fluorouracil + Leucovorin + Oxaliplatin A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (OrigAMI-1) Recruiting USA | ITA | ESP | DEU | CAN | BEL 5
NCT02576431 Phase II Larotrectinib A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) Completed USA | TUR | SWE | SVK | ITA | IRL | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG 9
NCT06172478 Phase II Patritumab deruxtecan A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting USA | NOR | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS 4
NCT02122913 Phase I Larotrectinib A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer Completed USA 0
NCT02637687 Phase I Larotrectinib A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children (SCOUT) Active, not recruiting USA | TUR | SWE | POL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | AUS 4
NCT01639508 Phase II Cabozantinib Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity Recruiting USA 0
NCT06532032 Phase Ib/II Amivantamab-vmjw + Docetaxel A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer (swalloWTail) Completed USA | TUR | GBR 1
NCT07017829 Phase II GT103 + Pembrolizumab GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer Recruiting USA 0
NCT05313009 Phase Ib/II Sotorasib + TH-4000 Tarlox and Sotorasib in Patients With KRAS G12C Mutations Terminated USA 0
NCT06528691 Phase II Entrectinib Carboplatin + Cyclophosphamide + Etoposide + Filgrastim Carboplatin + Cyclophosphamide + Etoposide + Pegfilgrastim Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors Recruiting USA | BRA 2
NCT02587650 Phase II Ceritinib Capmatinib Regorafenib Entrectinib Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma Terminated USA 0
NCT05241873 Phase Ib/II BLU-451 (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations Terminated USA | CAN 3
NCT05064280 Phase II Lenvatinib + Pembrolizumab Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases Recruiting USA 0
NCT02650401 Phase I Entrectinib Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN 2
NCT04085315 Phase I Alisertib + Osimertinib Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer Recruiting USA 0
NCT06364917 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC Recruiting USA 0
NCT01804530 Phase I PLX7486 Gemcitabine + Nab-paclitaxel Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors Terminated USA 0
NCT07227025 Phase Ib/II Amivantamab-vmjw + LY3537982 A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer (KaRAnaSa) Recruiting USA | TUR | CAN 2
NCT03066661 Expanded access Entrectinib Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions No longer available USA 0
NCT04827576 Phase II Docetaxel + Magrolimab Study of Magrolimab in Patients With Solid Tumors (ELEVATELung&UC) Terminated USA | POL | GBR | FRA | ESP 0
NCT05886920 Phase Ib/II D3S-001 + D3S-002 D3S-002 A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations Recruiting USA | AUS 2
NCT06946797 Phase II Paclitaxel Cisplatin Pemetrexed Disodium Carboplatin Ipilimumab + Nivolumab A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) (CheckMate-1533) Active, not recruiting USA | ROU | POL | ITA | GRC | FRA | BRA 2
NCT07222566 Phase III SSGJ-707 Pembrolizumab Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Recruiting USA | TUR | POL | ITA | ISR | HUN | GRC | FRA | ESP | DEU | CZE | CAN | BRA | AUS | ARG 5
NCT06644768 Phase Ib/II Pembrolizumab DS-3201b + Pembrolizumab A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations Recruiting USA | BRA | ARG 3
NCT05781308 Phase II Atezolizumab + Bevacizumab + Paclitaxel Bevacizumab + Paclitaxel Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy (ADAPTABLE) Active, not recruiting FRA 0
NCT03834961 Phase II Larotrectinib Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia Active, not recruiting USA | CAN 0
NCT05589818 Phase II Pembrolizumab Pembrolizumab for Advanced NSCLC and PS 2-3 Recruiting USA 0
NCT05159245 Phase II Vemurafenib Tepotinib Vismodegib Apalutamide Alectinib Regorafenib Entrectinib Pertuzumab + Trastuzumab Pemigatinib Atezolizumab Cobimetinib Dabrafenib + Trametinib Dabrafenib Trametinib Abemaciclib The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE) Recruiting FIN 0
NCT06216301 Phase III Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC (LUNAR-2) Recruiting USA | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CHE | BEL | AUT 2
NCT06822543 Phase II Carboplatin + Datopotamab deruxtecan + Pembrolizumab A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer) (TROPICAL-1) Recruiting BRA 0
NCT05117242 Phase II Acasunlimab + Pembrolizumab Acasunlimab Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer Active, not recruiting USA | POL | NLD | ITA | GBR | FRA | ESP | DEU 1
NCT06625775 Phase I BBO-10203 + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin BBO-10203 + Trastuzumab BBO-10203 + Fulvestrant + Ribociclib BBO-10203 Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors Recruiting USA | FRA | ESP | BRA | AUS 0
NCT02465060 Phase II Erdafitinib Trametinib Crizotinib Sapanisertib Fexagratinib Dasatinib Osimertinib Palbociclib Capivasertib Larotrectinib Ulixertinib Nivolumab + Relatlimab Copanlisib Sunitinib Nivolumab Pertuzumab + Trastuzumab Ipatasertib Dabrafenib + Trametinib Binimetinib Adavosertib Afatinib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Taselisib Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Active, not recruiting USA 2
NCT05077800 Phase II Elraglusib + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Losartan + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Elraglusib + Fluorouracil + Irinotecan + Leucovorin + Losartan + Oxaliplatin FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer Active, not recruiting USA 0
NCT05541822 Phase II ABN401 + Lazertinib ABN401 To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation Recruiting USA 2
NCT03639714 Phase Ib/II GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab A Study of a Personalized Neoantigen Cancer Vaccine Completed USA | AUS 0
NCT06074588 Phase III Docetaxel Sacituzumab tirumotecan Pemetrexed Disodium Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) Active, not recruiting USA | TUR | POL | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUS 11
NCT05215340 Phase III Pembrolizumab Datopotamab deruxtecan + Pembrolizumab Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08) Active, not recruiting USA | TUR | ROU | POL | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG 9
NCT05200481 Phase II Brigatinib + Carboplatin + Pemetrexed Disodium Brigatinib Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK) (MP-ALK) Active, not recruiting FRA 0
NCT04862780 Phase Ib/II BLU-945 BLU-945 + Osimertinib (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC Terminated USA | NLD | GBR | FRA | ESP | CAN 4
NCT07405190 Phase II Ivonescimab Carboplatin + Ivonescimab + Pemetrexed Disodium Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC Not yet recruiting USA 0
NCT05597800 Phase II Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome (LUNGVIR) Not yet recruiting ITA 0
NCT04083976 Phase II Erdafitinib A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR) Completed USA | POL | ITA | GBR | FRA | ESP | DEU | BRA | BEL | AUS | ARG 4
NCT06758401 Phase III Pembrolizumab Pembrolizumab + SGN-B6A This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. (Be6A Lung-02) Recruiting USA | TUR | SVK | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG 7
NCT06561386 Phase III Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nivolumab + Pemetrexed Disodium + Relatlimab A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 1-49% (RELATIVITY1093) Recruiting USA | TUR | ROU | POL | NZL | NLD | ITA | IRL | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG 11
NCT04211337 Phase III Vandetanib Cabozantinib Selpercatinib A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) Active, not recruiting USA | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS 5
NCT04094610 Phase Ib/II Repotrectinib A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations Recruiting USA | ITA | GBR | FRA | ESP | DNK | CAN | AUS 3